The Genetic Blueprint of ADSD

Autosomal Dominant Striatal Degeneration (ADSD) is fundamentally a “typo” in your genetic code. To understand why it affects your movement and what it means for your family, you have to look at the specific instructions being misread in your cells.

The PDE8B Gene: A Signal Controller

The PDE8B gene is responsible for making an enzyme that acts like a “reset button” for chemical signals in the brain ^[1]. Specifically, it breaks down a molecule called cAMP, which helps nerve cells in the striatum (the brain’s movement center) respond to dopamine ^[1][2].

In people with ADSD, the mutation is often a pathogenic variant (and sometimes a nonsense variant) ^[3][4]. You might see terms like heterozygous on your report, which simply means you have one healthy copy of the gene and one mutated copy ^[3]. A nonsense mutation acts like a premature “stop” sign in the middle of a sentence. This causes the cell to produce a broken, shortened version of the enzyme—or sometimes, no enzyme at all ^[4]. This is known as a loss-of-function mechanism: the brain loses its ability to properly regulate those cAMP signals, though the exact cellular pathology remains incompletely characterized ^[3][1].

What “Autosomal Dominant” Means for Your Family

The term autosomal dominant describes how this condition is passed from one generation to the next:

• Autosomal: The gene is located on one of the numbered chromosomes (not the sex chromosomes), meaning it can affect men and women equally.
• Dominant: You only need one mutated copy of the gene (out of the pair) to be at risk for developing the condition ^[3].

If a parent carries a PDE8B mutation, there is a 50% chance with each pregnancy that the child will inherit the mutation ^[3]. It is important to know that inheriting the gene does not mean symptoms will appear immediately, as penetrance is poorly defined.

Presymptomatic Carriers

Because ADSD progresses so slowly and usually begins in adulthood, it is possible for a relative to carry the mutation without showing any outward signs of movement trouble ^[3]. These individuals are a person who carries a pathogenic variant but has no symptoms ^[4].

Research using advanced brain imaging has shown that even when a person feels perfectly healthy, the “silent” gene may already be causing subtle changes in the brain ^[3]. In some very limited research observations, MRI or DTI (Diffusion Tensor Imaging) scans have detected “noisy” signals or changes in the brain’s wiring in carriers who have not yet developed parkinsonism ^[3][4]. However, imaging cannot currently predict if or when symptoms will develop.

Navigating Genetic Testing and Counseling

If you have been diagnosed, your relatives may face the difficult decision of whether or not to be tested. This process is called cascade testing—testing family members down the “cascade” of the family tree ^[5]. Predictive testing of asymptomatic adult relatives should be voluntary and preceded by counseling.

• Genetic Counseling: Before any family members get tested, it is highly recommended they meet with a genetic counselor. This professional helps families understand the psychological, financial (such as life and disability insurance, which vary by jurisdiction), and medical implications of a positive result ^[6][7].
• What to Look for on Reports: When reviewing results, look for the specific variant classification. Not all variants in the PDE8B gene cause ADSD; simple “missense” variants (small changes) are common in the general population and may be harmless, though some can be pathogenic ^[3][1]. Expert interpretation is required to confirm if a specific variant is truly “pathogenic” (disease-causing) ^[8]. A Variant of Uncertain Significance (VUS) cannot be used for predictive testing or clinical decisions.
• Reproductive Options: For those planning families, knowing the genetic cause allows for options such as preimplantation genetic testing (PGT), which can identify embryos that did not inherit the mutation ^[9].

The Pathology: What We Know

While scientists are still learning about the exact “footprints” ADSD leaves in the brain, a primary finding is the degeneration or wasting away of the striatum ^[4]. ADSD is primarily identified through imaging that shows the striatum becoming smaller or showing an abnormal signal on an MRI ^[3][4], but MRI signal or atrophy is not the same as neuropathologic proof. Understanding this genetic root is the first step toward one day finding a way to stabilize these signals and protect the brain.